Chronic heart failure – specifics of treating seniors

Česká verzia

Authors: L. Pavlíčková; A. Cybulja
Published in the journal: Geriatrie a Gerontologie 2015, 4, č. 2: 74-80
Category: Review Article

Summary

Heart failure is a serious disease with a higher prevalence in senior age. There are several drug classes, which are recommended for the treatment of chronic heart failure. In this article we discuss these drugs and also mention specific aspects of pharmacotherapy in seniors. We also mention the possibilities of non-surgical device treatment and cardio-surgical interventions. At the end we discuss palliative care approach, which is appropriate for the treatment of irreversible terminal heart failure.

Keywords:
heart failure – pharmacotherapy – palliative care

Zdroje

1. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart 2007; 93: 1137–1146.

2. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med 1971; 285(26): 1441–1446.

3. Spinar J, Vitovec J, Hradec J, a kol. Doporučený postup České kardiologické společnosti pro diagnostiku a léčbu chronického srdečního selhání, 2011. Cor et Vasa 2012; 54: 113–134.

4. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Committee for Practice Guidelines. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Eur Heart J 2012; 33(14): 1787–1847.

5. Hunt SA, Abraham WT, Chin MH, et al. Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2009; 119: 391–479.

6. Cheng JW, Nayar M. A review of heart failure management in the elderly population. Am J Geriatr Pharmacother 2009; 7(5): 233–249.

7. Woo KS, Nicholls MG. High prevalence of persistent cough with angiotensin converting enzyme inhibitors in Chinese. Br J Clin Pharmacol 1995; 40: 141–144.

8. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med 1992; 117: 234–242.

9. Pilote L, Abrahamowicz M, Eisenberg M. Effect of different angiotensin-converting-enzyme inhibitors on mortality among elderly patients with congestive heart failure. CMAJ 2008; 178(10): 1303–1311.

10. Dulin BR, Haas SJ, Abraham WT, Krum H. Do elderly systolic heart failure patients benefit from beta-blockers to the same extent as the non-elderly? Meta-analysis of >12,000 patients in large-scale clinical trials. Am J Cardiol 2005; 95: 896–898.

11. Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005; 26: 215–225.

12. Cleland JGF, Coletta AP, Torabi A, Clark AL. Clinical trials update from the European Society of Cardiology heart failure meeting 2009: CHANCE, B-Convinced, CHAT, CIBISELD and Signal HF. Eur J Heart Fail 2009; 11(8): 802–805.

13. Kubesova HM, Weber P, Meluzinova H, et al. Benefits and pitfalls of cardiovascular medication in seniors. Wien Klin Wochenschr 2013; 125(15–16): 425–436.

14. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709–717.

15. Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364: 11–21.

16. Pitt B, Remme W, Zannad F. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309–1321.

17. Murray MD, Haag KM, Black PK, et al. Variable furosemide absorption and poor predictability of response in elderly patients. Pharmacotherapy 1997; 17: 98–106.

18. Leto L, Aspromonte N, Feola M. Efficacy and safety of loop diuretic therapy in acute decompensated heart failure: a clinical review. Heart Fail Rev 2014; 19(2): 237–246.

19. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336: 525–533.

20. Hood WB Jr, Dans AL, Guyatt GH, et al. Digitalis for treatment of congestive heart failure in patients in sinus rhythm: a systematic review and meta-analysis. J Card Fail 2004; 10: 155–164.

21. Fialova D, Topinkova E, Gambassi G, et al. Potentially inappropriate medication use among elderly home care patients in Europe. JAMA 2005; 293(11): 1348–1358.

22. Rathore SS, Curtis JP, Wang Y, et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 2003; 289: 871– 878.

23. www.sukl.cz/modules/medication/detail.php?code=0083318&tab=texts

24. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. N Engl J Med 1986; 314: 1547–1552.

25. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 303–310.

26. Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004; 351: 2049–2057.

27. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369–2429.

28. Kjekshus J, Apetrei E, Barrios V. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007; 357: 2248–2261.

29. Tavazzi L, Maggioni AP, Marchioli R. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial). Lancet 2008; 372: 1231–1239.

30. Swedberg K, Komajda M, Bohm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT). Lancet 2010; 376: 875–885.

31. Jaarsma T, Beattie JM, Ryder M, et al. Palliative care in heart failure: a position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2009; 11: 433–443.

32. www.who.int/cancer/palliative/en